SCHEMBL13314770

SCHEMBL13314770

O=C(Nc1ccc(Nc2c[nH]nc2-c2ccccn2)nc1)C1CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.54
RAB9A P51151 9/20 0.54
ALDH1A1 P00352 4/20 0.54
TP53 P04637 3/20 0.54
PKM P14618 2/20 0.54
SMN1; SMN2 Q16637 5/20 0.49
ADORA2A P29274 2/20 0.48
ADORA2B P29275 2/20 0.48
ADORA1 P30542 2/20 0.48
TSHR P16473 2/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
PTBP1 P26599 1/20 0.47
ABL1 P00519 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPT P10636 2/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588187 0.85 AURKA (0.54) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL3588644 0.77 NNMT (0.43)
SCHEMBL3584456 0.75 MEN1 (0.37) NPC1RAB9ATP53PKMSMN1; SMN2
SCHEMBL3575559 0.72 MEN1 (0.53) NPC1RAB9AALDH1A1PKMSMN1; SMN2
SCHEMBL13314749 0.71 SMN1; SMN2 (0.50) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL3588865 0.71 KMT2A (0.45) NPC1RAB9AALDH1A1PKMSMN1; SMN2
SCHEMBL22258960 0.69 CYP3A4 (0.41) ALDH1A1TP53TSHRLMNAMAPT
SCHEMBL3579872 0.69 ALDH1A1 (0.47) NPC1RAB9AALDH1A1TP53PKM
SCHEMBL23719268 0.69 ADORA3 (0.51) NPC1RAB9ATP53SMN1; SMN2ADORA2A
SCHEMBL22258773 0.69 RAB9A (0.39) NPC1RAB9AALDH1A1SMN1; SMN2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES CDK1, CDK3, CDK13 NPC1 3024/4885RAB9A 3141/4885ALDH1A1 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.